A vaccine to immunise people against high levels of cholesterol and the narrowing of the arteries caused by build-up of fatty material (atherosclerosis) may be possible following successful results in mice. Now, a phase I trial in patients has started to see if the findings translate to humans.
The study, which is published today (Tuesday) in the European Heart Journal, is the first to show that it is possible to immunise genetically modified mice with a molecule that causes the body to produce antibodies against an enzyme called PCSK9 (Proprotein covertase subtilisin/kexin type 9), which plays a role in preventing the clearance of low density lipoprotein cholesterol (“bad” cholesterol) from the blood.
People with high levels of LDL cholesterol, either due to their genetic inheritance, or to poor diet and lifestyles, are at much greater risk of developing cardiovascular disease prematurely. These diseases of the heart and blood vessels, caused by atherosclerosis, have overtaken infections as the main cause of illness and death throughout the world. At present, drugs such as statins can be used to lower LDL cholesterol, but they have to be taken on a daily basis and although they are generally well-tolerated they can cause adverse side effects in some people. The most recently approved cholesterol-lowering compounds are monoclonal antibodies targeting PCSK9, which are highly effective, but their effect is short-lived, resulting in frequent re-application and high costs.
The research published today shows that the AT04A vaccine, when injected under the skin in mice that have been fed fatty, Western-style food in order to induce high cholesterol and the development of atherosclerosis, reduced the total amount of cholesterol by 53%, shrank atherosclerotic damage to blood vessels by 64%, and reduced biological markers of blood vessel inflammation by 21-28%, compared to unvaccinated mice. Furthermore, the induced antibodies remained functional over the whole study period and concentrations were still high at the end of the study.
Dr Günther Staffler, chief technology officer at AFFiRis (the company that developed AT04A) and one of the authors of the study, said: “AT04A was able to induce antibodies that specifically targeted the enzyme PCSK9 throughout the study period in the circulation of the treated mice. As a consequence, levels of cholesterol were reduced in a consistent and long-lasting way, resulting in a reduction of fatty deposits in the arteries and atherosclerotic damage, as well as reduced arterial wall inflammation.
“The reduction in total cholesterol levels was significantly correlated with induced antibody concentration, proving that induced antibodies caused the reduction in cholesterol and also are ultimately responsible for the reduction of atherosclerosis development. As antibody concentrations remained high at the end of the study, it can be assumed they would continue to reduce cholesterol levels for some time afterwards, resulting in a long-lasting effect, as has been shown in previous studies.
“If these findings translate successfully into humans, this could mean that, as the induced antibodies persist for months after a vaccination, we could develop a long-lasting therapy that, after the first vaccination, just needs an annual booster. This would result in an effective and more convenient treatment for patients, as well as higher patient compliance.”
The enzyme PCSK9 is made in the liver and it locks on to LDL cholesterol receptors, reducing their ability to get rid of LDL cholesterol from the blood. When injected, AT04A causes the body to produce antibodies that block the function of PCSK9, so that the activity of the LDL cholesterol receptors is increased.
“The way that AT04A is administered is comparable to a vaccine,” explained Dr Staffler. “However, the difference between a conventional vaccine and our approach is that a vaccine induces antibodies that are specific to bacterial or viral proteins that are foreign to the body – pathogens – whereas AT04A induces antibodies against a target protein that is produced by the body – endogenous proteins. This it is really an immunotherapeutic approach rather than a vaccine approach.”
In 2015, a phase I clinical study started at the Department of Clinical Pharmacology, Medical University of Vienna, Austria, studying AT04A and another molecule AT06A in 72 healthy people to assess its safety and activity. The study is expected to complete at the end of this year.
In an accompanying editorial, Professor Ulrich Laufs, of Saarland University, Germany, and Professor Brian Ference, of the University of Bristol, UK, and the Wayne State University School of Medicine, Detroit, USA, write: “It appears promising to further evaluate long-term LDL cholesterol lowering by vaccination against PCSK9 for the prevention of atherosclerotic events.” However, they say that “safety, the response in humans and the very important but unknown long-term immune effects need to be very carefully addressed during the course of clinical development”. In particular, reductions in total cholesterol via statins and other drugs are associated with an increase in new onset diabetes. “Therefore, one potential safety concern for long-term lowering of LDL cholesterol with a vaccine directed against PCSK9 is the potential for an increased risk of new onset diabetes. In the short term, the LDL cholesterol lowering effect of statins and PCS9 inhibitors appears to far outweigh the risks of new onset diabetes.”
Learn more: Vaccine that lowers cholesterol in mice offers hope of immunising against cardiovascular disease
The Latest on: Vaccine against high levels of cholesterol
[google_news title=”” keyword=”Vaccine against high levels of cholesterol” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- New influenza vaccine strategies aim to enhance protection with T-cell responseson May 5, 2024 at 11:13 pm
A recent review highlights the need for innovative influenza vaccines that combine T-cell and antibody responses to enhance protection across multiple strains and seasons.
- A vaccine to fight antibiotic resistanceon April 23, 2024 at 5:00 pm
Huang and his collaborators found that the two most promising PNAG pentasaccharides offered high levels of protection in mice against staph and MRSA. In animal studies, the team's new vaccine ...
- What’s the Connection Between High Blood Cholesterol and Hypertension?on April 22, 2024 at 4:59 pm
High levels of cholesterol may gradually clog your arteries ... high blood pressure is when “the force of your blood pushing against the wall of your blood vessels is consistently too high.” ...
- RSV Vaccine Could Protect High-Risk Adults Under 60, Pfizer Sayson April 9, 2024 at 7:47 am
Participants in the late-stage trial had increased levels of antibodies that fight against the two main ... company is also studying the vaccine’s response in high-risk children ages 2 to ...
- New affordable vaccine to lower cholesterol levels can be a game-changeron December 23, 2023 at 10:33 am
Researchers at the University of New Mexico have developed an affordable vaccine to lower cholesterol levels. The vaccination, according to the university, lowers the risk of heart attack and stroke ...
- What to Know About High Cholesterol and COVID-19on May 31, 2023 at 10:41 am
If you are obese or have high cholesterol levels ... maximize your protection against the disease and its negative health impacts. All FDA-approved or authorized vaccine candidates—Pfizer ...
- FDA: Novavax Covid-19 Vaccine Is Now Authorized For Ages 12 To 17on August 21, 2022 at 7:43 pm
these days the effectiveness of the Novavax may not be quite as high. Future studies will be needed to determine exactly how effective the vaccine will be against the BA.5 Omicron subvariant ...
- Indian variant: Vaccines offer ‘high level of protection'on May 23, 2021 at 3:07 am
Dr Mary Ramsay, head of immunisation at PHE, added: “This study provides reassurance that two doses of either vaccine offer high levels of protection against symptomatic disease from the B1617.2 ...
- Vaccines ‘offer high levels of protection against Indian variant’on May 23, 2021 at 2:06 am
The Pfizer coronavirus vaccine is 88 per cent effective ... while PHE said it expects to see even higher levels of effectiveness against hospital admission and death. The study, which took ...
- Healthy Foods That Are High in Cholesterolon October 13, 2019 at 5:00 pm
When you eat foods high in cholesterol, your liver produces less (2). For this reason, cholesterol in the diet has only minor effects on blood cholesterol levels in most people (2). However ...
via Google News and Bing News